NASDAQ · MTVA
Healthcare · Biotechnology
$1.48
Up+$0.01 (+0.68%)
Updated Oct 7, 2026, 5:38 PM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · MTVA
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
MTVA closed at $1.48 after 21 trading sessions, down 12.94% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $1.52 | $1.54 | $1.45 | $1.48 | 86.79K |
| Oct 5, 2026 | $1.55 | $1.5872 | $1.54 | $1.54 | 53.61K |
| Oct 2, 2026 | $1.56 | $1.65 | $1.51 | $1.54 | 64.26K |
| Oct 1, 2026 | $1.59 | $1.605 | $1.52 | $1.54 | 47.05K |
| Sep 30, 2026 | $1.64 | $1.66 | $1.55 | $1.57 | 65.62K |
| Sep 29, 2026 | $1.64 | $1.67 | $1.61 | $1.66 | 26.07K |
| Sep 28, 2026 | $1.65 | $1.70 | $1.62 | $1.67 | 134.99K |
| Sep 25, 2026 | $1.68 | $1.68 | $1.61 | $1.66 | 28.75K |
| Sep 24, 2026 | $1.6617 | $1.6617 | $1.61 | $1.63 | 65.33K |
| Sep 23, 2026 | $1.65 | $1.665 | $1.61 | $1.63 | 38.44K |
| Sep 22, 2026 | $1.69 | $1.69 | $1.64 | $1.68 | 31.61K |
| Sep 21, 2026 | $1.65 | $1.7007 | $1.64 | $1.67 | 45.29K |
| Sep 18, 2026 | $1.55 | $1.73 | $1.55 | $1.73 | 108.68K |
| Sep 17, 2026 | $1.5505 | $1.59 | $1.52 | $1.59 | 39.25K |
| Sep 16, 2026 | $1.5701 | $1.5901 | $1.52 | $1.54 | 46.27K |
| Sep 15, 2026 | $1.67 | $1.67 | $1.5601 | $1.58 | 53.53K |
| Sep 14, 2026 | $1.64 | $1.87 | $1.60 | $1.62 | 76.76K |
| Sep 11, 2026 | $1.75 | $1.7949 | $1.65 | $1.66 | 57.12K |
| Sep 10, 2026 | $1.75 | $1.83 | $1.7402 | $1.75 | 105.08K |
| Sep 9, 2026 | $1.70 | $1.8499 | $1.52 | $1.74 | 609.82K |
| Sep 8, 2026 | $1.76 | $1.81 | $1.70 | $1.70 | 43.53K |
The latest Smart Investors Daily articles mentioning MTVA.
Company
Market Activity
Research & News
MTVA research
Company profile and research snapshot.
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 10, 2026 | HC Wainwright & Co. | Buy | — |
| May 18, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 27, 2026 | HC Wainwright & Co. | Buy | — |
| Jan 6, 2026 | HC Wainwright & Co. | Buy | — |
| May 19, 2025 | Maxim Group | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 10, 2026
By David Bautz, PhD NASDAQ: MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Preclinical Results Provide Insight into DA-1726 Mechanism of Waist Reduction On September 9, 2026, MetaVia, Inc. (NASDAQ: MTVA) announced the results of a preclinical study utilizing radioactively labeled DA-1726 to evaluate its tissue distribution following subcutaneous administration. The results showed that
Yahoo · Sep 9, 2026
MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced results from a preclinical tissue distribution study demonstrating that DA-1726-derived radioactivity is slowly absorbed and extensively distributed throughout the body following subcutaneous administration, with broad tissue distribution and the highest tissue exposure observed in adipose (fat) tissue.
Yahoo · Aug 12, 2026
By David Bautz, PhD NASDAQ: MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Dose Titration Complete in Phase 1 Part 3 Study of DA-1726 MetaVia, Inc. (NASDAQ: MTVA) is currently conducting Part 3 of the Phase 1 study of DA-1726, the company’s oxyntomodulin analog agonist that targets glucagon-like peptide-1 receptors (GLP1R) and glucagon receptors (GCGR), for the treatment of obesity. The
Benzinga · Aug 6, 2026
MetaVia (NASDAQ:MTVA) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of $(0.82) by 9.76 percent. This is a 68.53 percent increase over losses of $(2.86) per share from the
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MTVA.
